A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc. In addition, we have a diversified portfolio of multiple compounds in mid- to late-phase development across our core therapeutic areas and an expanding early-phase pipeline that includes a range of modalities including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.9B | 2.9B | 2.4B | 1.9B | 1.5B | 1.1B |
| Net Income | 479M | 479M | 341M | 250M | 155M | 90M |
| EPS | $4.67 | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
| Free Cash Flow | 749M | 749M | 557M | 362M | 323M | 233M |
| ROIC | 13.9% | 22.4% | 23.7% | 14.8% | 18.0% | 10.3% |
| Gross Margin | 98.2% | 98.2% | 98.6% | 94.9% | 98.4% | 63.6% |
| Debt/Equity | 0.14 | 0.14 | 0.19 | 0.21 | 0.16 | 0.33 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 619M | 619M | 571M | 251M | 249M | 103M |
| Operating Margin | 21.6% | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| ROE | 14.7% | 16.4% | 14.2% | 12.7% | 10.0% | 7.2% |
| Shares Outstanding | 102M | 102M | 104M | 101M | 99M | 97M |
NEUROCRINE BIOSCIENCES INC passes 5 of 9 quality checks, suggesting mixed fundamentals.
NEUROCRINE BIOSCIENCES INC trades at 27.0x trailing earnings, compared to its 15-year median P/E of 47.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 16.9x vs a median of 36.7x. The company's 5-year average ROIC is 17.8% with a gross margin of 90.7%. Total shareholder yield (buybacks) is 1.3%. At current prices, the estimated annualized return to fair value is +33.1%.
NEUROCRINE BIOSCIENCES INC (NBIX) has a current P/E ratio of 27.0, compared to its historical median P/E of 47.9. The stock is currently considered Fair based on its historical valuation range.
NEUROCRINE BIOSCIENCES INC (NBIX) has a 5-year average return on invested capital (ROIC) of 17.8%. This indicates strong capital allocation and a potential competitive advantage.
NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of $12.9B. It is classified as a large-cap stock.
NEUROCRINE BIOSCIENCES INC (NBIX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.30%.
Based on historical P/E analysis, NEUROCRINE BIOSCIENCES INC (NBIX) appears fair. The current P/E of 27.0 is 44% below its historical median of 47.9. The estimated fair value CAGR (P/E method) is 28.3%.
NEUROCRINE BIOSCIENCES INC (NBIX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
NEUROCRINE BIOSCIENCES INC (NBIX) reported annual revenue of $2.9 billion in its most recent fiscal year, based on SEC EDGAR filings.
NEUROCRINE BIOSCIENCES INC (NBIX) has a net profit margin of 16.7%. This is a healthy margin.
NEUROCRINE BIOSCIENCES INC (NBIX) generated $749 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
NEUROCRINE BIOSCIENCES INC (NBIX) has a debt-to-equity ratio of 0.14. This indicates a conservatively financed balance sheet.
NEUROCRINE BIOSCIENCES INC (NBIX) reported earnings per share (EPS) of $4.67 in its most recent fiscal year.
NEUROCRINE BIOSCIENCES INC (NBIX) has a return on equity (ROE) of 16.4%. This indicates the company generates strong returns for shareholders.
NEUROCRINE BIOSCIENCES INC (NBIX) has a 5-year average gross margin of 90.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for NEUROCRINE BIOSCIENCES INC (NBIX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NEUROCRINE BIOSCIENCES INC (NBIX) has a book value per share of $31.74, based on its most recent annual SEC filing.